Browse the evidence

Participants who sat for 8 or more hours per day experienced a 17% to 50% higher associated risk of the composite outcome across physical activity levels.

Encouraging reduced sitting time is crucial, even for those who are physically active.

Obesity is a disease that results in impaired quality of life and reduced life expectancy.

Healthcare practitioners should recognize obesity as a disease and address its impacts on quality of life and longevity.

Two-thirds of obesity-related excess mortality is attributable to cardiovascular disease.

Public health initiatives should focus on reducing obesity to lower cardiovascular disease mortality.

Obesity has been underrecognized and sub-optimally addressed compared to other cardiovascular risk factors.

Healthcare providers should prioritize the recognition and management of obesity as a key cardiovascular risk factor.

Most relative risks (RRs) for protective associations ranged from 0.87 to 0.96 per daily serving change, while harmful associations ranged from 1.06 to 1.15 per daily serving change.

Understanding these RRs can help in making informed dietary choices to mitigate CMD risk.

Most identified associations were protective (n = 38) and a smaller number were harmful (n = 24), with a higher risk associated with higher intake.

Emphasizing protective dietary factors can aid in reducing CMD risk.

Food insecurity is a powerful social determinant of health that impacts health outcomes.

Addressing food insecurity is crucial for improving health outcomes.

Discontinuing GLP-1RA treatment leads to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those prescribed semaglutide/tirzepatide.

Practitioners should consider the likelihood of weight regain when discontinuing GLP-1RA therapy.

The proportion of weight regained after discontinuation of GLP-1RA therapy is proportional to the amount originally lost.

Weight loss strategies should account for the likelihood of proportional weight regain after stopping GLP-1RA therapy.

Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions.

Clinicians should inform patients that stopping GLP-1RA may lead to weight regain despite lifestyle efforts.

Endoscopic sleeve gastroplasty (ESG) is more cost-effective than semaglutide over a 5-year time horizon, with an incremental cost-effectiveness ratio (ICER) of -$595,532/QALY.

Practitioners may consider ESG as a more cost-effective option for treating class II obesity compared to semaglutide.

Over 10 years, the MTM intervention is anticipated to potentially be associated with 18,257,000 averted hospitalizations and reductions in health care expenditures of $484.5 billion.

Long-term implementation of MTMs could significantly reduce hospitalizations and healthcare costs.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.

Vegan diets can be health-promoting and may offer certain important advantages compared to typical Western eating patterns.

Health professionals should recognize the potential health benefits of vegan diets.

A precise and practical vegan nutrition guide for health professionals is lacking.

There is an urgent need for health professionals to have access to a vegan nutrition guide.

There is no single mode of physical activity that is superior for weight loss or prevention of weight gain.

Advise clients that various forms of physical activity can be effective for weight management, and they should choose what they enjoy.

Fewer serious adverse events were reported with semaglutide compared to placebo.

Semaglutide may be a safer option for patients compared to placebo.

Resistance training (RT) to set failure is likely not superior to non-failure RT for inducing muscle hypertrophy.

Practitioners may consider non-failure RT as effective for muscle hypertrophy.

Nonelderly males with overweight and obesity experience a reduction in skeletal muscle mass of about 2 to 2.5 kg per 10-kg weight loss during voluntary caloric restriction.

Practitioners should be aware that caloric restriction can lead to significant muscle loss in males, which may need to be addressed in weight loss programs.

Nonelderly females with overweight and obesity experience a reduction in skeletal muscle mass of about 1 to 1.5 kg per 10-kg weight loss during voluntary caloric restriction.

Practitioners should be aware that caloric restriction can lead to significant muscle loss in females, which may need to be addressed in weight loss programs.

The study suggests reassessing the preoperative withholding guidelines for GLP-1 receptor agonists.

Healthcare providers may need to update their protocols regarding GLP-1 RA use before surgery.

Tirzepatide provides better value for money than semaglutide for weight reduction.

Healthcare providers may prefer prescribing tirzepatide over semaglutide for weight management.

The mean total costs over 2 years were lower for MBS ($51,794) compared to GLP-1 receptor agonists ($63,483).

MBS may offer a more cost-effective long-term solution for obesity treatment.

The intervention group was more likely to achieve gestational weight gain (GWG) within recommendations compared to the control group (OR = 1.51; 95% CI (0.81, 2.80)).

Practitioners may consider structured nutrition and exercise interventions to help pregnant women achieve recommended weight gain.